In CLL patients, high-expression of CSNK2A1 was associated with early need for therapy (n = 130, p < 0.0001) and short overall survival (OS; n = 107, p = 0.005). This evidence concerns the gene CSNK2A1 and B-cell chronic lymphocytic leukemia.